Oleg Andreev

Biography

2013-present: Professor, Physics Department, University of Rhode Island.
2013-present: Professor Adjunct, Department of Radiation Oncology, Rhode Island Hospital, Warren Alpert Brown Medical School.
2012-2019: Chair, Physics Department, University of Rhode Island.
2009-2013: Associate Professor, Physics Department, University of Rhode Island.
2007–2009: Assistant Professor, Physics Department, University of Rhode Island.
2005–2007: Research Assistant Professor, Physics Department, University of Rhode Island.
2004–2005: Visiting Scientist, Department of Molecular Biophysics and Biochemistry, Yale
2003–2004: Senior Research Scientist, Sopherion Theraputics, Inc
1996–2003: Research Assistant Professor, Department of Molecular Biology and Immunology, North Texas University
1996: Associate Biophysicist, Baylor University Medical Center at Dallas
1995–1996: Faculty Research Associate, University of Texas at Austin
1993–1995: Associate Biophysicist, Baylor University Medical Center at Dallas

Research

Biological physics: membrane biophysics, molecular motors, fluorescent microscopy, fluorescence polarization imaging, spectral analysis from cells, electric cell substrate impedance sensing on cells

Medical physics and nanotechnology: pH-imaging, novel approaches in drug delivery and tumor targeting, clinical fluorescent imaging and instumentation, delivery of nanopores to cancer cells, hyperthermia.

Education

  • Postdoctoral Research Associate, Baylor University Medical Center, Dallas, 1990-1993
  • Ph.D. in Physics and Mathematics (Biological Physics), Moscow Institute of Physics and Technology, Moscow, Russia, 1990
  • M.S. in Physics, Moscow Institute of Physics and Technology, Moscow, Russia, 1979

Selected Publications

1: Reshetnyak YK, Andreev OA, Engelman DM. Aiming the magic bullet: targeted
delivery of imaging and therapeutic agents to solid tumors by pHLIP peptides.
Front Pharmacol. 2024 Mar 13;15:1355893. doi: 10.3389/fphar.2024.1355893. PMID:
38545547; PMCID: PMC10965573.

2: Moshnikova A, DuPont M, Iraca M, Klumpp C, Visca H, Allababidi D, Pelzer P,
Engelman DM, Andreev OA, Reshetnyak YK. Targeted intracellular delivery of
dimeric STINGa by two pHLIP peptides for treatment of solid tumors. Front
Pharmacol. 2024 Mar 1;15:1346756. doi: 10.3389/fphar.2024.1346756. PMID:
38495104; PMCID: PMC10940318.

3: DuPont M, Klumpp C, Iraca M, Allababidi D, Visca H, Engelman DM, Andreev OA,
Moshnikova A, Reshetnyak YK. pHLIP targeted intracellular delivery of
calicheamicin. Int J Pharm. 2024 Apr 10;654:123954. doi:
10.1016/j.ijpharm.2024.123954. Epub 2024 Feb 28. PMID: 38428548.

4: Matsui T, Toda Y, Sato H, Itagaki R, Konishi K, Moshnikova A, Andreev OA,
Hosogi S, Reshetnyak YK, Ashihara E. Targeting acidic pre-metastatic niche in
lungs by pH low insertion peptide and its utility for anti-metastatic therapy.
Front Oncol. 2023 Nov 15;13:1258442. doi: 10.3389/fonc.2023.1258442. PMID:
38033489; PMCID: PMC10684925.

5: Silva TFD, Visca H, Klumpp C, Andreev OA, Reshetnyak YK, Machuqueiro M.
Arginine Residues Modulate the Membrane Interactions of pHLIP Peptides. J Chem
Inf Model. 2023 Jul 24;63(14):4433-4446. doi: 10.1021/acs.jcim.3c00360. Epub
2023 Jul 3. PMID: 37395685; PMCID: PMC10369490.

6: DuPont M, Visca H, Moshnikova A, Engelman DM, Reshetnyak YK, Andreev OA.
Tumor treatment by pHLIP-targeted antigen delivery. Front Bioeng Biotechnol.
2023 Jan 6;10:1082290. doi: 10.3389/fbioe.2022.1082290. PMID: 36686229; PMCID:
PMC9853002.

7: Moshnikova A, Golijanin B, Amin A, Doyle J, Kott O, Gershman B, DuPont M, Li
Y, Lu X, Engelman DM, Andreev OA, Reshetnyak YK, Golijanin D. Targeting Bladder
Urothelial Carcinoma with pHLIP-ICG and Inhibition of Urothelial Cancer Cell
Proliferation by pHLIP-amanitin. Front Urol. 2022;2:868919. doi:
10.3389/fruro.2022.868919. Epub 2022 Aug 24. PMID: 36439552; PMCID: PMC9691284.

8: Moshnikova A, DuPont M, Visca H, Engelman DM, Andreev OA, Reshetnyak YK.
Eradication of tumors and development of anti-cancer immunity using STINGa
targeted by pHLIP. Front Oncol. 2022 Oct 18;12:1023959. doi:
10.3389/fonc.2022.1023959. PMID: 36330464; PMCID: PMC9622777.

9: Bauer D, Visca H, Weerakkody A, Carter LM, Samuels Z, Kaminsky S, Andreev OA,
Reshetnyak YK, Lewis JS. PET Imaging of Acidic Tumor Environment With
89Zr-labeled pHLIP Probes. Front Oncol. 2022 May 19;12:882541. doi:
10.3389/fonc.2022.882541. PMID: 35664740; PMCID: PMC9160799.

10: Visca H, DuPont M, Moshnikova A, Crawford T, Engelman DM, Andreev OA,
Reshetnyak YK. pHLIP Peptides Target Acidity in Activated Macrophages. Mol
Imaging Biol. 2022 Dec;24(6):874-885. doi: 10.1007/s11307-022-01737-x. Epub 2022
May 23. PMID: 35604527; PMCID: PMC9681937.

11: Zhang X, Rotllan N, Canfrán-Duque A, Sun J, Toczek J, Moshnikova A, Malik S,
Price NL, Araldi E, Zhong W, Sadeghi MM, Andreev OA, Bahal R, Reshetnyak YK,
Suárez Y, Fernández-Hernando C. Targeted Suppression of miRNA-33 Using pHLIP
Improves Atherosclerosis Regression. Circ Res. 2022 Jun 24;131(1):77-90. doi:
10.1161/CIRCRESAHA.121.320296. Epub 2022 May 9. PMID: 35534923; PMCID:
PMC9640270.

12: Hulikova A, Park KC, Loonat AA, Gunadasa-Rohling M, Curtis MK, Chung YJ,
Wilson A, Carr CA, Trafford AW, Fournier M, Moshnikova A, Andreev OA, Reshetnyak
YK, Riley PR, Smart N, Milne TA, Crump NT, Swietach P. Alkaline nucleoplasm
facilitates contractile gene expression in the mammalian heart. Basic Res
Cardiol. 2022 Mar 31;117(1):17. doi: 10.1007/s00395-022-00924-9. PMID: 35357563;
PMCID: PMC8971196.

13: Wilson AD, Richards MA, Curtis MK, Gunadasa-Rohling M, Monterisi S, Loonat
AA, Miller JJ, Ball V, Lewis A, Tyler DJ, Moshnikova A, Andreev OA, Reshetnyak
YK, Carr C, Swietach P. Acidic environments trigger intracellular H+-sensing FAK
proteins to re-balance sarcolemmal acid-base transporters and auto-regulate
cardiomyocyte pH. Cardiovasc Res. 2022 Nov 10;118(14):2946-2959. doi:
10.1093/cvr/cvab364. PMID: 34897412; PMCID: PMC9648823.

14: Gayle S, Aiello R, Leelatian N, Beckta JM, Bechtold J, Bourassa P, Csengery
J, Maguire RJ, Marshall D, Sundaram RK, Van Doorn J, Jones K, Moore H, Lopresti-
Morrow L, Paradis T, Tylaska L, Zhang Q, Visca H, Reshetnyak YK, Andreev OA,
Engelman DM, Glazer PM, Bindra RS, Paralkar VM. Correction to ‘Tumor-selective,
antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor
conjugate suppresses tumor growth without systemic toxicity’. NAR Cancer. 2021
Dec 7;3(4):zcab047. doi: 10.1093/narcan/zcab047. Erratum for: NAR Cancer. 2021
Jun 04;3(2):zcab021. doi: 10.1093/narcan/zcab021. PMID: 34888524; PMCID:
PMC8651162.

15: Gayle S, Aiello R, Leelatian N, Beckta JM, Bechtold J, Bourassa P, Csengery
J, Maguire RJ, Marshall D, Sundaram RK, Van Doorn J, Jones K, Moore H, Lopresti-
Morrow L, Paradis T, Tylaska L, Zhang Q, Visca H, Reshetnyak YK, Andreev OA,
Engelman DM, Glazer PM, Bindra RS, Paralkar VM. Tumor-selective, antigen-
independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate
suppresses tumor growth without systemic toxicity. NAR Cancer. 2021 Jun
4;3(2):zcab021. doi: 10.1093/narcan/zcab021. Erratum in: NAR Cancer. 2021 Dec
07;3(4):zcab047. doi: 10.1093/narcan/zcab047. PMID: 34316708; PMCID: PMC8210154.

16: Crawford T, Moshnikova A, Roles S, Weerakkody D, DuPont M, Carter LM, Shen
J, Engelman DM, Lewis JS, Andreev OA, Reshetnyak YK. pHLIP ICG for delineation
of tumors and blood flow during fluorescence-guided surgery. Sci Rep. 2020 Oct
27;10(1):18356. doi: 10.1038/s41598-020-75443-5. PMID: 33110131; PMCID:
PMC7591906.

17: Wu H, Estrella V, Beatty M, Abrahams D, El-Kenawi A, Russell S, Ibrahim-
Hashim A, Longo DL, Reshetnyak YK, Moshnikova A, Andreev OA, Luddy K, Damaghi M,
Kodumudi K, Pillai SR, Enriquez-Navas P, Pilon-Thomas S, Swietach P, Gillies RJ.
T-cells produce acidic niches in lymph nodes to suppress their own effector
functions. Nat Commun. 2020 Aug 17;11(1):4113. doi: 10.1038/s41467-020-17756-7.
PMID: 32807791; PMCID: PMC7431837.

18: Reshetnyak YK, Moshnikova A, Andreev OA, Engelman DM. Targeting Acidic
Diseased Tissues by pH-Triggered Membrane-Associated Peptide Folding. Front
Bioeng Biotechnol. 2020 Apr 28;8:335. doi: 10.3389/fbioe.2020.00335. PMID:
32411684; PMCID: PMC7198868.

19: Slaybaugh G, Weerakkody D, Engelman DM, Andreev OA, Reshetnyak YK. Kinetics
of pHLIP peptide insertion into and exit from a membrane. Proc Natl Acad Sci U S
A. 2020 Jun 2;117(22):12095-12100. doi: 10.1073/pnas.1917857117. Epub 2020 May
14. PMID: 32409607; PMCID: PMC7275707.

20: Henry KE, Chaney AM, Nagle VL, Cropper HC, Mozaffari S, Slaybaugh G, Parang
K, Andreev OA, Reshetnyak YK, James ML, Lewis JS. Demarcation of Sepsis-Induced
Peripheral and Central Acidosis with pH (Low) Insertion Cycle Peptide. J Nucl
Med. 2020 Sep;61(9):1361-1368. doi: 10.2967/jnumed.119.233072. Epub 2020 Jan 31.
PMID: 32005774; PMCID: PMC7456172.

21: Price NL, Miguel V, Ding W, Singh AK, Malik S, Rotllan N, Moshnikova A,
Toczek J, Zeiss C, Sadeghi MM, Arias N, Baldán Á, Andreev OA, Rodríguez-Puyol D,
Bahal R, Reshetnyak YK, Suárez Y, Fernández-Hernando C, Lamas S. Genetic
deficiency or pharmacological inhibition of miR-33 protects from kidney
fibrosis. JCI Insight. 2019 Nov 14;4(22):e131102. doi:
10.1172/jci.insight.131102. PMID: 31613798; PMCID: PMC6948871.

22: Wei D, Engelman DM, Reshetnyak YK, Andreev OA. Mapping pH at Cancer Cell
Surfaces. Mol Imaging Biol. 2019 Dec;21(6):1020-1025. doi:
10.1007/s11307-019-01335-4. PMID: 30989440; PMCID: PMC9258692.

23: Brito J, Golijanin B, Kott O, Moshnikova A, Mueller-Leonhard C, Gershman B,
Andreev OA, Reshetnyak YK, Amin A, Golijanin D. Ex-vivo Imaging of Upper Tract
Urothelial Carcinoma Using Novel pH Low Insertion Peptide (Variant 3), a
Molecular Imaging Probe. Urology. 2020 May;139:134-140. doi:
10.1016/j.urology.2019.01.008. Epub 2019 Jan 16. PMID: 30659902; PMCID:
PMC8882055.

Awards and Honors:

2016-2020: NIH grant R01, GM073857, $2,282,802
2018: URI outstanding inventor
2017: URI Research and Scholarship Excellence Award
2016: Maitland P. Simmons Memorial Research Award
2016: URI Research and Scholarship Excellence Award
2015: URI Excellence Award
2014: URI outstanding inventor
2013: URI outstanding inventor
2012: Maitland P. Simmons Memorial Research Award
2012: URI outstanding inventor
2011: Maitland P. Simmons Memorial Research Award
2010: URI outstanding inventor
2006: URI outstanding inventor